Science✓ Verified

By making key signaling molecules called β-arrestins into druggable targets, scientists crack long-standing challenge

Reported byPhys.org ↗·Sourced by Goodlede

What backs it

Scientists have identified β-arrestins as viable drug targets, solving a decades-long challenge in GPCR drug development that affects roughly one-third of all FDA-approved medications and opens new therapeutic pathways.

Systemic / trendWell established✓ Verified

Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.

Read the full story at Phys.org

Read original story ↗

By making key signaling molecules called β-arrestins into druggable targets, scientists crack long-standing challenge

More good news, verified daily.